WallStreetZenWallStreetZen

NASDAQ: SPRY
Ars Pharmaceuticals Inc Stock Ownership - Who owns Ars Pharmaceuticals?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Ars Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Eric KarasChief Commercial Officer2025-07-0115,000$1.50
$22.50kBuy
Eric KarasChief Commercial Officer2025-07-0115,000$16.99
$254.87kSell
James E. Flynn10% Owner2025-06-27370,074$18.46
$6.83MSell
James E. Flynn10% Owner2025-06-27370,075$18.46
$6.83MSell
Eric KarasChief Commercial Officer2025-06-1815,000$16.00
$240.00kSell
Eric KarasChief Commercial Officer2025-06-1815,000$1.50
$22.50kBuy
Brent L. SaundersDirector2025-05-20120,000$1.01
$121.20kBuy
Alexander A. FitzpatrickChief Legal Officer2025-05-20100,000$5.58
$558.00kBuy
Brent L. SaundersDirector2025-05-20120,000$14.25
$1.71MSell
Kathleen D. ScottChief Financial Officer2025-05-2050,000$1.50
$75.00kBuy

1 of 16

SPRY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SPRY insiders and whales buy or sell their stock.

SPRY Shareholders

What type of owners hold Ars Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC17.34%17,029,398$302.27MInsider
Peter A. Thompson17.34%17,029,398$302.27MInsider
Richard E. Lowenthal14.55%14,291,828$253.68MInsider
Sarina Tanimoto12.88%12,649,635$224.53MInsider
Ra Capital Management LP11.06%10,860,977$192.78MInstitution
Deerfield Management Company LP Series C10.71%10,514,657$186.64MInstitution
James E. Flynn9.95%9,774,508$173.50MInsider
Orbimed Advisors LLC8.44%8,288,510$147.12MInstitution
Pratik Shah4.91%4,824,554$85.64MInsider
Jonathan D. Root4.53%4,445,960$78.92MInsider

1 of 3

SPRY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SPRY45.94%54.06%Net SellingNet Selling
ARQT76.98%23.02%Net SellingNet Selling
BCRX82.35%17.65%Net SellingNet Buying
MESO0.33%0.00%
IMCR95.30%4.33%Net Buying
View Top Biotech Stocks

Ars Pharmaceuticals Stock Ownership FAQ

Who owns Ars Pharmaceuticals?

Ars Pharmaceuticals (NASDAQ: SPRY) is owned by 77.61% institutional shareholders, 91.33% Ars Pharmaceuticals insiders, and 0.00% retail investors. Orbimed Advisors LLC is the largest individual Ars Pharmaceuticals shareholder, owning 17.03M shares representing 17.34% of the company. Orbimed Advisors LLC's Ars Pharmaceuticals shares are currently valued at $304.49M.

If you're new to stock investing, here's how to buy Ars Pharmaceuticals stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.